RGEN Price Prediction Next Week
Analysis and Insights
Technical Analysis:
Repligen (RGEN) is currently trading at $152.5 as of 2025-03-10. Based on the technical indicators:
- RSI (6, 12, 14): 44.98, 47.82, 48.24 respectively, indicating the stock is in a bearish range but not oversold.
- Stochastic Oscillator: %K (56.07) is above %D (53.77), suggesting a potential bullish crossover.
- MACD: The MACD line (0.11) is slightly above the signal line (0.03), indicating weak bullish momentum.
- Bollinger Bands: The stock is near the lower band, suggesting it may be undervalued and due for a bounce.
News and Analyst Sentiment:
- Analyst Ratings: Multiple analysts have maintained a Buy rating on RGEN, with price targets ranging from $165 to $200. The average target is $173.75, indicating a potential upside of approximately 14% from current levels.
- Company News: Repligen has made strategic acquisitions and launched new products, which are expected to drive growth.
Price Prediction and Recommendation:
Based on the technical indicators and analyst sentiment, RGEN is expected to rise slightly in the next trading week. The stock is likely to test the upper Bollinger Band and potentially reach $158. Given the positive analyst outlook and the stock's current valuation, it is recommended to Buy RGEN at its current price level.
RGEN Similar Chart Price Prediction
The price of RGEN is predicted to go up -2.8%, based on the high correlation periods with AIRI. The similarity of these two price pattern on the periods is 93.88%.
RGEN
AIRI
Down: -2.8%Similarity: 93.88%
RGEN Revenue Forecast
RGEN EPS Forecast
RGEN FAQs
What is RGEN revenue forecast for next quarter？
What is RGEN eps forecast for next quarter？
RGEN Analyst's Forecast
Kyle Mikson
Canaccord Genuity
Hold
2025-02-21
Price Target
$165 → $170
Upside
+6.92%
Canaccord raised the firm's price target on Repligen to $170 from $165 and keeps a Buy rating on the shares. The firm said they reported solid Q4 results and are encouraged by the company's commentary regarding orders, leading to a solid initial outlook for 2025.
Doug Schenkel
Wolfe Research
Hold
2024-11-14
Price Target
n/a
Downside
0%
